NEW YORK (GenomeWeb) – Leerink today initiated coverage of liquid biopsy-based diagnostics firm Trovagene with an Outperform rating. 

Analyst Dan Leonard gave the San Diego-based company's shares a $9 price target, and in a report, he noted the sizeable liquid biopsy market opportunity — which he pegged at a minimum of $10 billion long term — calling it "a market with the potential … to be the largest in molecular diagnostics." 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.